Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank combines the immunogenic tuftsin fragment with a Pro-Gly-Pro tripeptide to enhance metabolic stability. Research highlights anxiolytic activity comparable to benzodiazepines but without addictive potential, sedation, or cognitive impairment.
